Overview

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Transgene